Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TPMT | P51580 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31697364 | 1.00 | MTOR (0.45) | MTORMAPTTDP1CES2CES1 | |
| SCHEMBL3561298 | 0.83 | CES2 (0.37) | MAPTTDP1CES2CES1HTT | |
| SCHEMBL590030 | 0.81 | TPMT (0.52) | MTORMAPTTDP1SMN1; SMN2TPMT | |
| SCHEMBL29602624 | 0.81 | TPMT (0.52) | MTORMAPTTDP1SMN1; SMN2TPMT | |
| SCHEMBL17325043 | 0.81 | MTOR (0.50) | MTORMAPTTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL25779809 | 0.80 | TPMT (0.39) | MTORCES2CES1TPMTALDH1A1 | |
| SCHEMBL40769 | 0.80 | SMN1; SMN2 (0.55) | MAPTTDP1CES2CES1HTT | |
| SCHEMBL30475402 | 0.80 | SMN1; SMN2 (0.55) | MAPTTDP1CES2CES1HTT | |
| SCHEMBL1233265 | 0.79 | MTOR (0.49) | MTORMAPTTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16891406 | 0.79 | MTOR (0.45) | MTORMAPTTDP1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988389-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2018-06-05 | — | — | US | claimed |
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2018-02-15 | — | — | US | claimed |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-15 | — | — | US | claimed |
| WO-2016201203-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-12-15 | — | — | WO | claimed |
| US-9493473-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2016-11-15 | — | — | US | claimed |
| CN-103044432-B | Bicyclic heteroaryl compounds | 阿里亚德医药股份有限公司 | 2016-08-03 | — | — | CN | claimed |
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-04-21 | — | — | US | claimed |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE, LLC (US) | 2014-11-20 | — | — | US | claimed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | claimed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-10-14 | — | — | US | disclosed |
| US-12398142-B2 | Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases | EMORY UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | disclosed |
| CN-1087291-C | N-hydroxyureas as anti-inflammatory agents | PFIZER (US) | 2002-07-10 | — | — | CN | disclosed |
| EP-0832078-B1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5814648-A | N-hydroxyureas as antiinflammatory agents | PFIZER INC. (US) | 1998-09-29 | — | — | US | disclosed |
| CN-1191531-A | N-hydroxyureas as antiinflammatory agents | PFIZER (US) | 1998-08-26 | — | — | CN | disclosed |
| EP-0832078-A1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040659-A1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | MTOR 237/4885MAPT 4409/4885TDP1 614/4885 |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | MTOR 237/4885MAPT 4409/4885TDP1 614/4885 |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | BRAF, RAF1, NRAS | MTOR 934/4885MAPT 4072/4885TDP1 1623/4885 |
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | MTOR 195/4885MAPT 4157/4885TDP1 646/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | MTOR 488/4885MAPT 4109/4885TDP1 3147/4885 |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | MTOR 195/4885MAPT 4157/4885TDP1 646/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | MTOR 3713/4885MAPT 2300/4885TDP1 3904/4885 |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | MYLK, MFAP1, FIBP | MTOR 3442/4885MAPT 4699/4885TDP1 3726/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | MTOR 169/4885MAPT 2333/4885TDP1 1725/4885 |
| US-12398142-B2 | Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases | ABL2, ABL1, FYN | MTOR 644/4885MAPT 174/4885TDP1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.